Risk of thrombosis and hemorrhage in patients with polycythemia vera and atrial fibrillation treated with prophylactic oral anticoagulants.

dc.contributor.author de Freitas, Ana Sofiaca
dc.contributor.author Álvarez Larrán, Albertoca
dc.date.accessioned 2017-03-14T11:29:07Z
dc.date.issued 2016
dc.description.abstract Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by an expansion of red cell mass which leads to an increased risk of thrombotic and hemorrhagic complications.ca
dc.description.sponsorship This work was supported by a grant from the Instituto de Salud Carlos III, PI13/00557.
dc.format.mimetype application/pdfca
dc.identifier.citation de Freitas AS, Alvarez-Larrán A. Risk of thrombosis and hemorrhage in patients with polycythemia vera and atrial fibrillation treated with prophylactic oral anticoagulants. Ann Hematol. 2016 Oct;95(11):1903-4. DOI: 10.1007/s00277-016-2783-yca
dc.identifier.doi http://dx.doi.org/10.1007/s00277-016-2783-y
dc.identifier.issn 0939-5555
dc.identifier.uri http://hdl.handle.net/10230/28224
dc.language.iso engca
dc.publisher Springerca
dc.relation.ispartof Annals of Hematology. 2016 Oct;95(11):1903-4
dc.rights.accessRights info:eu-repo/semantics/openAccessca
dc.subject.other Trombosica
dc.subject.other Hemorràgiaca
dc.subject.other Policitèmia veraca
dc.title Risk of thrombosis and hemorrhage in patients with polycythemia vera and atrial fibrillation treated with prophylactic oral anticoagulants.ca
dc.type info:eu-repo/semantics/articleca
dc.type.version info:eu-repo/semantics/acceptedVersionca

Col·leccions